S. Arroyo[REV NEUROL 2000;31:728-732]PMID: 12497347DOI: https://doi.org/10.33588/rn.3108.2000383OPEN ACCESS
Volumen 31 |
Number 08 |
Nº of views of the article 5.386 |
Nº of PDF downloads 73 |
Article publication date 16/10/2000
OBJECTIVE. Observational studies are necessary for evaluation of the efficacy and safety of the new antiepileptic drugs. Unlike blind, randomised studies, observational studies are carried out in populations of less resistant patients in normal clinical practice. Therefore these trials give valuable information regarding the efficacy and safety of antiepileptic drugs.
PATIENTS AND METHODS A multicentre trial was carried out in Spain in which patients with partial epilepsy treated with one or more antiepileptic drugs were also given tiagabine. Tiagabine was started at a dose of 5 mg per day and increased weekly by 5 mg until the dose considered suitable or a maximum of 70 mg per day was reached. Data were collected on the aetiology of the seizures, their frequency and type and the presence of sideeffects. The study was planned to take place over one year, but this paper is being written after six months followup.
RESULTS We studied 645 patients with an average age of 35.4 years. The average duration of their epilepsy was 18.3 years and 76.6% of patients had previously received three or more antiepileptic drugs. The average dose of tiagabine reached during the maintenance period was 32.6 mg/day. After six months of treatment 29.4% of the patients had had no seizures during the last three months of the trial and 67% of the population had a reduction in seizures of over 50%. Some form of sideeffect was seen in 52.4% of the patients during the study period. The commonest of these was somnolence (28.2% of the patients) but fainting (23.4%) and difficulty in paying attention/concentration were seen less frequently (15%). In most cases the sideeffects were transient or slight (tolerable). No patient had nonconvulsive illness. During the study tiagabine was stopped in 166 patients (25.7% of the total) due to lack of efficacy or intolerance. CONCLUSION. Tiagabine is effective, well tolerated addon therapy in patients with partial epilepsy.
KeywordsAnticonvulsantAntiepileptic drugsEpilepsyPartial seizuresTiagabineCategoriesEpilepsias y síndromes epilépticos
FULL TEXT(solo disponible en lengua castellana / Only available in Spanish)
Si ya es un usuario registrado en Neurologia, introduzca sus datos de inicio de sesión.
Rellene los campos para registrarse en Neurologia.com y acceder a todos nuestros artículos de forma gratuita
¿Olvidó su contraseña? Introduzca su correo electrónico y le haremos llegar una nueva
¡CONVIÉRTASE EN USUARIO PREMIUM DE NEUROLOGIA.COM!
Al hacerse premium, está apoyándonos para que Revista de Neurología
siga siendo uno de los referentes de habla hispana en la difusión del
conocimiento en neurociencias. ¡Gratuita tanto para autores como para
todos los usuarios de la web!
Además, por convertirte en usuario premium, recibirá las siguientes ventajas:
Plaza asegurada en todos nuestros Másteres (www.ineurocampus.com)
Descuento del 5% en los cursos de “Actualización en Neurología”, la FMC que estará disponible próximamente en la web.
Descarga gratuita en formato PDF dos de las obras con más éxito publicadas por Viguera Editores:
Oromotors Disorders in childhood (M. Roig-Quilis; L. Pennington)
Manual de Neuropsicología 2ª ed. (J. Tirapu-Ustárroz; M. Ríos-Lago; F. Maestú)
El precio para hacerse Premium durante el periodo de un año es de 5€, que podrá pagar a continuación a través de una pasarela de pago seguro con tarjeta de crédito, transferencia bancaria o PayPal:
OPEN ACCESS
